Coverage and specificity
Tumor clearance efficiency
1. It should be high enough, and it is possible to obtain CRR response using antibodies or CAR-T therapy against this target.
2. Refer to the efficacy of related antibody drugs.
3. Test patients’ samples before the treatment.
1. It is limited to tumor tissue, or the damage caused by off-tumor toxicity can be tolerated or well managed.
2. Refer to the side effect of related antibody drugs.
Response duration and recurrence
1. The expression should be stable and not easily regulated by external signals.
2. It plays an important role in the growth and survival of cancer cells.